SiRNA下调组织蛋白酶B抑制甲状腺乳头状癌细胞的增殖、迁移及侵袭能力

中华养生保健 ›› 2025, Vol. 43 ›› Issue (2): 42-46.

SiRNA下调组织蛋白酶B抑制甲状腺乳头状癌细胞的增殖、迁移及侵袭能力

黄婷婷¹, 孙坚皓², 杜君慧¹, 吕艳春¹, 孙琳琳¹, 张凤英^1,*

1.潍坊中医院耳鼻咽喉科,山东潍坊, 261000;
2.潍坊中医院脊柱外科,山东潍坊, 261000

出版日期:2025-01-16 发布日期:2025-01-23
通讯作者: ^*张凤英,E-mail：Zhangfengying1979@163.com。
作者简介:黄婷婷（1991—）,女,汉族,籍贯：山东省滕州市,硕士研究生,主治医师,研究方向：耳鼻咽喉头颈外科方向。
基金资助:
潍坊市卫生健康委员会科研项目（WFWSJK-2021-010）

Silencing of Cathepsin B Inhibits Biological Characteristics of Papillary Thyroid Carcinoma Cells

HUANG Ting-ting¹, SUN Jian-hao², DU Jun-hui¹, LYU Yan-chun¹, SUN Lin-lin¹, ZHANG Feng-ying^1,*

1. Department of Otolaryngology, Weifang Hospital of Traditional Chinese Medicine, Weifang 261000, Shandong, China;
2. Department of Spinal Surgery, Weifang Hospital of Traditional Chinese Medicine, Weifang 261000, China

Online:2025-01-16 Published:2025-01-23

摘要/Abstract

摘要： 目的探究小干扰RNA下调组织蛋白酶B（Cathepsin B;CTSB;CB）对甲状腺乳头状癌TPC-1细胞的增殖、迁移及侵袭能力的影响。方法将TPC-1细胞分成空白对照组、SiRNA-1组（转染CB-siRNA-1）;SiRNA-2组（转染CB-siRNA-2）;SiRNA-3组（转染CB-siRNA-3）;NC组（转染NC-siRNA）,通过Western blot法检测CB表达;通过CCK-8、平板单克隆实验、细胞划痕实验及Transwell实验检测细胞增殖、迁移及侵袭能力。结果 Western blot结果显示,实验组CB表达较空白组及阴性对照组明显下降,差异有统计学意义（P<0.05）。沉默CB后细胞增殖、迁移及侵袭能力明显减弱,差异有统计学意义（P<0.05）。结论本实验证实利用SiRNA沉默CB后,TPC-1细胞的增殖、迁移及侵袭能力明显减弱,说明CB可能成为PTC基因治疗的有效靶点。

关键词: 甲状腺乳头状癌, 组织蛋白酶B, 增殖, 侵袭, 迁移

Abstract: Objective To explore the effect of Cathepsin B on the proliferation, migration and invasion of papillary thyroid carcinoma TPC-1 cells. Methods The siRNA of targeting Cathepsin B was transiently transfected into TPC-1 cells and Western blot was used to detect the expression of Cathepsin B. Cell counting kit-8, colony formation assay, Wound-healing migration assay and transwell assay were used to detect cell proliferation, migration and invasion. Results Western blot results showed that the expression of Cathepsin B in the experimental group was significantly lower than that in the blank group and the negative control group, and the difference was statistically significant. After silencing Cathepsin B, the ability of cell proliferation, migration, and invasion were significantly weakened, and the difference was statistically significant. Conclusion This study confirmed that silencing Cathepsin B with SiRNA significantly decreased the proliferation, migration, and invasion of TPC-1 cells, indicating that Cathepsin B may be an effective target for papillary thyroid carcinoma gene therapy.

Key words: papillary thyroid carcinoma, cathepsin B, proliferation, invasion, migration

中图分类号:

R542.22

黄婷婷, 孙坚皓, 杜君慧, 吕艳春, 孙琳琳, 张凤英. SiRNA下调组织蛋白酶B抑制甲状腺乳头状癌细胞的增殖、迁移及侵袭能力[J]. 中华养生保健, 2025, 43(2): 42-46.

HUANG Ting-ting, SUN Jian-hao, DU Jun-hui, LYU Yan-chun, SUN Lin-lin, ZHANG Feng-ying. Silencing of Cathepsin B Inhibits Biological Characteristics of Papillary Thyroid Carcinoma Cells[J]. ZHONGHUA YANGSHENG BAOJIAN, 2025, 43(2): 42-46.

参考文献

[1] GU M.IL13Rα2 siRNA inhibited cell proliferation,induced cell apoptosis,and suppressed cell invasion in papillary thyroid carcinoma cells[J]. OncoTargets and Therapy,2018,(11):1345-1352.
[2] LANG B H, LO C Y, CHAN W F, et al.Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathologic features and long-term outcome[J]. World journal of surgery,2006,30(5):752-758.
[3] SEBASTIAN S O, RODRIGUEZ GONZALEZ J M, PARICIO P P, et al. Papillary Thyroid Carcinoma:Prognostic Index for Survival Including the Histological Variety[J]. Archives of Surgery,2000,135(3):272.
[4] LEONARDI G C, CANDIDO S, CARBONE M, et al.BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (Review)[J].Molecular Medicine Reports,2012,6(4):687-694.
[5] VALERIO L, PIERUZZI L, GIANI C, et al.Targeted Therapy in Thyroid Cancer: State of the Art[J]. Clinical oncology,2017,29(5):316-324.
[6] 赵雨,郁林娜,高庆军.甲状腺乳头状癌转移潜在相关蛋白及作用机制研究进展[J].中国普外基础及临床杂志,2019,4(26):503-507.
[7] BROWN L M, HELMKE S M, S W. H, et al. Quantitative and Qualitative Differences in Protein Expression Between Papillary Thyroid Carcinoma and Normal Thyroid Tissue[J]. Molecular carcinogenesis,2006,45(8):613-626.
[8] AGGARWAL N, SLOANE B F.Cathepsin B:multiple roles in cancer[J]. Proteomics.Clinical applications,2014;8(5-6):427-437.
[9] YANG W E, HO C C, YANG S F, et al.Cathepsin B Expression and the Correlation with Clinical Aspects of Oral Squamous Cell Carcinoma[J]. PloS one,2016,11(3):e0152165.
[10] YAN Y, ZHOU K, WANG L, et al.Clinical significance of serum cathepsin B and cystatin C levels and their ratio in the prognosis of patients with esophageal cancer[J]. OncoTargets and Therapy,2017,10:1947-1954.
[11] 查道德,涂龙霞,吴文涌.组织蛋白酶B联合TRAIL诱导胃癌BGC-823细胞凋亡的作用研究[J].包头医学院学报,2023,39(1):4-6.
[12] MITROVIC A, MIRKOVIC B, SOSIC I, et al.Inhibition of endopeptidase and exopeptidase activity of cathepsin B impairs extracellular matrix degradation and tumour invasion[J]. Biological chemistry,2016,397(2):165-174.
[13] BIAN B, MONGRAIN S, CAGNOL S, et al.Cathepsin B promotes colorectal tumorigenesis,cell invasion, and metastasis[J]. Molecular carcinogenesis,2016,55(5):671-687.
[14] GONDI C S, LAKKA S S, DINH D H, et al.RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas[J]. Oncogene,2004,23(52):8486-8496.
[15] BEARDS F, JONES L E, CHARNOCK J, et al.Placental homing peptide-microRNA inhibitor conjugates for targeted enhancement of intrinsic placental growth signaling[J]. Theranostics,2017,7(11):2940.
[16] STEFFAN J J, SNIDER J L, SKALLI O, et al.Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells[J].Traffic,2009,10(6):737-753.
[17] 张红,娄欣,曹学全,等.组织蛋白酶B特异性siRNA对人食管癌EC9706细胞体外侵袭力的抑制作用[J].郑州大学学报(医学版),2007,42(1):17.
[18] TEDELIND S, JORDANS S, RESEMANN H, et al.Cathepsin B trafficking in thyroid carcinoma cells[J]. Thyroid Research,2011,4:S2.
[19] ZHONG Y J, SHAO L H, LI Y.Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review)[J]. International journal of oncology. 2013,42(2):373-383.
[20] SATSANGI A, ROY S S, SATSANGI R K, et al.Synthesis of a novel, sequentially active-targeted drug delivery nanoplatform for breast cancer therapy[J]. Biomaterials,2015,59:88-101.